Investor Presentaiton
New solutions
Atrial Fibrillation SaMD
to launch Q2-2024
AHI plans to release Software-as-a-Medical-Device (SaMD)
Atrial Fibrillation scan as part of its Biometric health assessment
(BHA) from Q2-2024, as well as the Atrial Fibrillation scan a stand-
alone service.
FDA
SFDA
الهيئة العامة للغذاء والدواء
Saudi Food & Drug Authority
Administration
TGA
CERTIFIED
Therapeutic
Goods
of Australia
Investor Presentation - January 2024
The PPG fingerscan is a function of phase 2 and phase 4 of AHI's
BHA and will soon offer medically approved atrial-fibrillation
detection.
CE
The technology has medical approval in Australia, USA,
Singapore, EU, UK, UAE and Saudi Arabia for near clinical.
The global prevalence of atrial fibrillation (AF) is approximately 60
million cases, of which up to 40% AF patients are asymptomatic.
Source: https://wcsecure.weblink.com.au/clients/advancedhumanimaging/v2/headline.aspx?headlineid=61184064
17View entire presentation